Atrial natriuretic peptide
- Generic Name
- Atrial natriuretic peptide
- Drug Type
- Biotech
- CAS Number
- 85637-73-6
To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension
Phase 2
Recruiting
- Conditions
- Difficult to Control Hypertension
- Interventions
- Other: Placebo Matched control
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- E-Star BioTech, LLC
- Target Recruit Count
- 120
- Registration Number
- NCT06343298
- Locations
- ๐บ๐ธ
Amicis Research Center - Granada Hills, Granada Hills, California, United States
๐บ๐ธInterventional Cardiology Medical Group, West Hills, California, United States
๐บ๐ธOffice of Dr. Edward Portnoy MD, Westlake Village, California, United States
Enhancing the Natriuretic Peptide System in HFpEF
Phase 1
- Conditions
- Heart Failure with Preserved Ejection FractionChronic Kidney Diseases
- Interventions
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Horng Chen
- Target Recruit Count
- 60
- Registration Number
- NCT05279742
- Locations
- ๐บ๐ธ
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Safety And Tolerability Of Subcutaneous MANP In Difficult To Control/Resistant Hypertensive Subjects
Phase 1
Completed
- Conditions
- Resistant HypertensionDifficult to Control Hypertension
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- E-Star BioTech, LLC
- Target Recruit Count
- 37
- Registration Number
- NCT05247528
- Locations
- ๐บ๐ธ
USA Clinical Site 01, Tustin, California, United States
๐บ๐ธUSA Clinical Site 04, Decatur, Georgia, United States
๐บ๐ธUSA Clinical Site 05, Owensboro, Kentucky, United States
MANP in Hypertension and Metabolic Syndrome
- First Posted Date
- 2018-12-20
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 22
- Registration Number
- NCT03781739
- Locations
- ๐บ๐ธ
Mayo Foundation, Rochester, Minnesota, United States
Prevention of Akute Kidney Injury, Hearttransplant, ANP
- First Posted Date
- 2016-01-27
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Sahlgrenska University Hospital, Sweden
- Target Recruit Count
- 86
- Registration Number
- NCT02665377
- Locations
- ๐ธ๐ช
Sahlgrenska sjukhuset, Gothenburg, Sweden
Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma
- First Posted Date
- 2010-12-15
- Last Posted Date
- 2017-07-26
- Lead Sponsor
- Burzynski Research Institute
- Registration Number
- NCT01260103
Carperitide in Acute Respiratory Distress Syndrome (ARDS)
Phase 2
Completed
- Conditions
- Respiratory Distress Syndrome
- First Posted Date
- 2002-02-01
- Last Posted Date
- 2008-02-20
- Lead Sponsor
- Suntory Pharmaceutical
- Registration Number
- NCT00030121
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2025. All Rights Reserved by MedPath